Over the past year, Cristal Therapeutics has transitioned from a research-stage start-up to a fully fledged, clinical-stage business with a promising pipeline of proprietary drug candidates. This diverse pipeline together with the proprietary nanoparticle platform, CriPec®, presents a broad range of promising late- and early-stage partnering opportunities for companies active in the oncology space.
Victoria Morgan looks at the benefits of combining an active pharmaceutical product with a novel subcutaneous delivery device, and highlights some of the partnerships West has with biopharmaceutical and other companies, which have led to market launches of products incorporating its on-body delivery system.
Erin Miller outlines a study looking at how patients interact with training resources during the first 14 days of a new treatment – and how training devices can help increase confidence, adherence and, ultimately, overall outcomes for the millions of patients who manage their diseases through self-injection.
Elektrofi introduces Elektroject™, a gentle process for the production of ultra-high concentration protein formulations, that maintains a syringeable format and excellent protein stability, making the switch from intravenous to subcutaneous delivery viable for numerous biotherapeutics, including monoclonal antibodies.
Bjarne Sørensen and John A. Merhige explore the latest developments in modular autoinjector platforms and the benefits for end users and pharmaceutical customers. They also discuss the two companies’ recent partnership for the development of a combined system that capitalises on important synergies between two compatible technologies.
David Belton discusses the meaning of quality by design in novel respiratory drug delivery device development. He covers how, with more novel devices, prior knowledge may be insufficient for a standard FMEA-style risk analysis, and alternate science-based methods, such as functional mapping and knowledge scoring, can help in achieving QbD.